News | Radiopharmaceuticals and Tracers | January 17, 2017

NorthStar Medical Technologies Receives Follow-on Award from National Nuclear Security Administration

Award furthers $50 million cooperative agreement supporting NorthStar Medical Radioisotopes’ accelerator method of producing Molybdenum-99

January 17, 2017 — NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) for its accelerator method of producing the medical radioisotope molybdenum-99 (Mo-99). The addition brings the total funding for the new method, in development by subisidiary NorthStar Medical Radioisotopes, to $11.1 million.

The award supports the process’ continued advancement toward commercialization and recognizes NorthStar’s progress toward its goal of offering multiple sources of Mo-99 produced in the United States using complementary processes that do not involve highly enriched uranium (HEU).

The award advances a $50 million cooperative agreement between the two organizations in which NorthStar raised $25 million that will be matched dollar-for-dollar by DOE/NNSA upon full funding of the agreement. NNSA had already fully funded a separate $50 million cooperative agreement supporting NorthStar’s neutron activation Mo-99 production method, which also does not use HEU as the target material.

Mo-99 is the parent isotope of technetium-99m (Tc-99m), the most widely used radioisotope in medical diagnostic imaging. Tc-99m is used in approximately 40 million procedures worldwide each year to diagnose and stage cancer, heart disease, infection, inflammation and other conditions. But while the United States accounts for roughly half of that demand, no Mo-99 has been produced domestically since 1989. All Mo-99 is currently produced overseas, much of it in aging reactors using weapons-usable HEU, creating safety and national security concerns and the risk of product shortages.

Both of NorthStar’s production methods use safe, non-radioactive target material and an external radiation source to convert a naturally occurring isotope of molybdenum into Mo-99 suitable for use in NorthStar’s proprietary RadioGenix isotope separation system. There, it decays to create Tc-99m. Both processes produce a low-volume, benign waste stream, making them “greener” than all other processes that use uranium-based targets.

Accelerator production is currently the most environmentally friendly method of Mo-99 generation; an electron beam from a linear accelerator (LINAC), rather than a fission reactor, is used as a radiation source to drive a reaction that converts molybdenum-100 to Mo-99. The neutron capture method uses neutrons from a fission reactor to convert molybdenum-98 to Mo-99.

In pairing the two production methods, NorthStar will ensure a steady supply of Mo-99 by mitigating the disruptions commonly experienced by single-method producers when faced with unexpected equipment downtime.

 

 

 

Read the 2017 article "FDA Clears Path for First Domestic Supply of Tc-99m Isotope." 

For more information: www.northstarnm.com

Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...